Immuno-oncology for bladder cancer has been around for more than four decades in the form of BCG intravesical therapy for NMIBC. For more advanced disease, systemic platinum-based chemotherapy has been the standard first-line treatment. While objective response rates are as high as 60%, and complete responses (CRs) occur in ~ 20% of patients, duration of response is brief. With a median overall survival of ~15 months and a 5-year survival rate of ≤15%, relapsed urothelial bladder cancer (UBC) represents a substantial unmet medical need.

Not surprisingly, UBC is particularly susceptible to immune checkpoint inhibitors (ICIs), with these agents demonstrating acceptable safety profiles that are often more tolerable than platinum-based chemotherapy. Beyond approved indications for ICIs, these agents are being studied in bladder-sparing regimens in multimodal combinations of interest to the urologist.

Selecting the appropriate agent for a given patient is important to obtain optimal efficacy. Ongoing debates related to ICI treatment include: how to use biomarkers to guide therapy selection, how best to sequence ICIs with other therapies, the appropriate duration of checkpoint inhibitor treatment, and how to stop/restart immunotherapy if interrupted by immune-related adverse events (irAEs). This session will highlight current best practices and emerging strategies, with interactive multidisciplinary panels where specialists in urology, medical oncology, and urologic oncology will debate hot topics of interest to the urologist actively managing UBC.


View All Speakers


Arjun Balar, MD

Director, Genitourinary Medical Oncology Program Laura and Isaac Perlmutter Cancer Center NYU Langone Health New York, New York
View Full Bio

Ashish Kamat, MD, MBBS, FACS (Activity Chair)

Professor, Department of Urology Wayne B. Duddlesten Professor of Cancer Research Associate Cancer Center Director, RFHNH, Mumbai University of Texas MD Anderson Cancer Center Houston, Texas
View Full Bio

Neal Shore, MD, FACS

Director and Certified Physician Investigator (CPI) Carolina Urologic Research Center Atlantic Urology Clinics Myrtle Beach, South Carolina
View Full Bio

Robert Dreicer, MD, MS, MACP, FASCO

Associate Director for Clinical Research Deputy Director, University of Virginia Cancer Center Section Head, Medical Oncology Co-Director, Paul Mellon Urologic Cancer Institute Professor of Medicine and Urology University of Virginia School of Medicine Charlottesville, Virginia
View Full Bio


In support of improving patient care, Creative Educational Concepts is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Medicine (ACCME)
CEC designates this live educational activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Upon completion of a CE Request Form, statements of credit for physicians will be issued within 30 business days.


Presented by Creative Educational Concepts, Inc., and the Bladder Cancer Advocacy Network (BCAN).

Supported by an independent educational grant from AstraZeneca.